Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 2, 2017, Pages 206-214

  Kadam, Rameshwar U ^a   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Arbidol; Fusion inhibitor; Hemagglutinin; Influenza virus; X ray crystallography

Indexed keywords

ARBIDOL; HYDROGEN; INFLUENZA VIRUS HEMAGGLUTININ; ANTIVIRUS AGENT; INDOLE DERIVATIVE; PROTEIN BINDING; VIRUS FUSION PROTEIN;

ALPHA HELIX; CARBOXY TERMINAL SEQUENCE; CONFERENCE PAPER; DRUG PROTEIN BINDING; ENDOSOME; HYDROGEN BOND; HYDROPHOBICITY; INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H7N9); INFLUENZA VIRUS; MEMBRANE FUSION; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN CONFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; PHYSIOLOGY;

ANTIVIRAL AGENTS; CRYSTALLIZATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INDOLES; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; MEMBRANE FUSION; MOLECULAR STRUCTURE; PROTEIN BINDING; VIRAL FUSION PROTEINS;

EID: 85009380300     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1617020114     Document Type: Article

References (45)

1. Beveridge WI (1991) The chronicle of influenza epidemics. Hist Philos Life Sci 13(2): 223-234.
2. Nguyen-Van-Tam JS, Hampson AW (2003) The epidemiology and clinical impact of pandemic influenza. Vaccine 21(16):1762-1768.
3. Salzberg S (2008) The contents of the syringe. Nature 454(7201):160-161.
4. Davlin SL, et al. (2016) Influenza activity -United States, 2015-16 season and composition of the 2016-17 influenza vaccine. MMWR Morb Mortal Wkly Rep 65(22): 567-575.
5. Hensley SE (2014) Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. Curr Opin Virol 8:85-89.
6. Houser K, Subbarao K (2015) Influenza vaccines: Challenges and solutions. Cell Host Microbe 17(3):295-300.
7. De Clercq E (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5(12):1015-1025.
8. Beigel J, Bray M (2008) Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 78(1):91-102.
9. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295(8):891-894.
10. Moscona A (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360(10):953-956.
11. Sheu TG, et al. (2011) Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J Infect Dis 203(1):13-17.
12. Wilson IA, Skehel JJ, Wiley DC (1981) Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289(5796):366-373.
13. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 69:531-569.
14. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ (2008) Arbidol: A broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15(10):997-1005.
15. Leneva IA, Fediakina IT, Guskova TA, Glushkov RG (2005) [Sensitivity of various influenza virus strains to Arbidol. Influence of Arbidol combination with different antiviral drugs on reproduction of influenza virus A]. Ter Arkh 77(8):84-88. Russian.
16. Leneva IA, et al. (2016) Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia. Int J Infect Dis 43:77-84.
17. Brooks MJ, et al. (2012) Antiviral activity of Arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 84(1): 170-181.
18. Shi L, et al. (2007) Antiviral activity of Arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 152(8):1447-1455.
19. Pecheur EI, et al. (2016) The synthetic antiviral drug Arbidol inhibits globally prevalent pathogenic viruses. J Virol 90(6):3086-3092.
20. Blaising J, Polyak SJ, Pecheur EI (2014) Arbidol as a broad-spectrum antiviral: An update. Antiviral Res 107:84-94.
21. Liu Q, et al. (2013) Antiviral and anti-inflammatory activity of Arbidol hydrochloride in influenza A (H1N1) virus infection. Acta Pharmacol Sin 34(8):1075-1083.
22. Leneva IA, Russell RJ, Boriskin YS, Hay AJ (2009) Characteristics of Arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of Arbidol. Antiviral Res 81(2):132-140.
23. Brancato V, et al. (2013) Design of inhibitors of influenza virus membrane fusion: Synthesis, structure-activity relationship and in vitro antiviral activity of a novel indole series. Antiviral Res 99(2):125-135.
24. Fadeeva NI, et al. (1992) Inhibitors of the early stages of virus-cell interactions among derivatives of 3-ethoxycarbonyl-5-hydroxy-6-bromoindole. Chem Pharma J 26(9): 676-680.
25. Nasser ZH, Swaminathan K, Muller P, Downard KM (2013) Inhibition of influenza hemagglutinin with the antiviral inhibitor Arbidol using a proteomics based approach and mass spectrometry. Antiviral Res 100(2):399-406.
26. Nishio M, Hirota M, Umezawa Y (1998) The CH/π Interaction: Evidence, Nature, and Consequences (Wiley-VCH, Weinheim), pp 1-232.
27. Levitt M, Perutz MF (1988) Aromatic rings act as hydrogen bond acceptors. J Mol Biol 201(4):751-754.
28. Kadam RU, et al. (2013) CH-π T-shape interaction with histidine explains binding of aromatic galactosides to Pseudomonas aeruginosa lectin LecA. ACS Chem Biol 8(9): 1925-1930.
29. Sobolev V, Sorokine A, Prilusky J, Abola EE, Edelman M (1999) Automated analysis of interatomic contacts in proteins. Bioinformatics 15(4):327-332.
30. Ekiert DC, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924):246-251.
31. Dreyfus C, et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337(6100):1343-1348.
32. Hoffman LR, Kuntz ID, White JM (1997) Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: Irreversible inhibition of infectivity. J Virol 71(11):8808-8820.
33. Russell RJ, et al. (2008) Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA 105(46):17736-17741.
34. Battles MB, et al. (2016) Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol 12(2):87-93.
35. Zhao Y, et al. (2016) Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535(7610):169-172.
36. Stevens J, et al. (2004) Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303(5665):1866-1870.
37. Ekiert DC, et al. (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489(7417):526-532.
38. Xu R, et al. (2013) Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science 342(6163):1230-1235.
39. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
40. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(Pt 4):658-674.
41. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58(Pt 11): 1948-1954.
42. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
43. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372(3):774-797.
44. Chen VB, et al. (2010) MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66(Pt 1):12-21.
45. Dundas J, et al. (2006) CASTp: Computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res 34(Web Server issue):W116-8.